This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Trametinib oral

Updated 2 Feb 2023 | MEK Inhibitor


Oral formulations of trametinib.

Drugs List

  • MEKINIST 0.5mg tablets
  • MEKINIST 2mg tablets
  • trametinib 0.5mg tablets
  • trametinib 2mg tablets
  • Therapeutic Indications


    Advanced non-small cell lung cancer BRAFV600 mutation:Combination treatment

    Monotherapy or in combination with dabrafenib in adults with unresectable or metastatic melanoma with a confirmed BRAF V600 mutation.

    Adjuvant treatment of melanoma
    In combination with dabrafenib in adults for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.

    Non-small cell lung cancer
    In combination with dabrafenib in adults with advanced non-small cell lung cancer with a confirmed BRAF V600 mutation.


    Whilst the doses stated below are those recommended by the manufacturer, local cancer network protocols for the relevant indication should be consulted.

    Patients should continue treatment until disease progression or unacceptable toxicity. In the adjuvant treatment of melanoma, patients should be treated for 12 months unless there is disease recurrence or unacceptable toxicity.

    When trametinib is given in combination with dabrafenib, dabrafenib product information must be consulted prior to initiation of treatment.


    2mg once a day.

    Additional Dosage Information

    Dose level reductions
    1st reduction: 1.5mg once a day.
    2nd reduction: 1mg once a day.
    Reductions below 1mg are not recommended.
    When used in combination with dabrafenib, consult dabrafenib product information for dabrafenib dose reductions.

    Once adverse reactions are under control, dose re-escalation following the same dosing steps as reduction may be considered.

    CTC-AE toxicity modification schedule for adverse reactions (excluding pyrexia)
    Grade 1 or Grade 2 (tolerable) toxicities: Continue treatment and monitor as clinically indicated.
    Grade 2 (intolerable) or grade 3 toxicities: Suspend treatment until symptoms have resolved to grade 1 or lower. Reduce dose by one dose level when resuming treatment.
    Grade 4 toxicities: Permanently discontinue or suspend treatment until symptoms resolve to grade 1 or lower, reduce dose by one dose level when resuming treatment.

    Interrupt treatment if the patient's temperature is greater than or equal to 38 degrees celsius. Treatment with anti-pyretics such as ibuprofen or paracetamol should be initiated. In cases where anti-pyretics are insufficient, oral corticosteroids should be considered. Patients should be evaluated for signs and symptoms of infection. If the patient is symptom free for at least 24 hours, trametinib should be restarted at the same dose level or reduced by one dose level if pyrexia is recurrent and/or accompanied by other severe symptoms including dehydration, hypotension or renal failure.

    Retinal pigment epithelial detachment (RPED)
    Grade 1 RPED: Continue treatment carrying out monthly retinal examinations until resolution.
    Grade 2 or 3 RPED: Withhold treatment for up to 3 weeks.
    Grade 2 or 3 RPED that improves to grade 1 or lower within 3 weeks: Resume treatment at a lower dose (0.5mg reduction) or discontinue trametinib in patients taking 1mg daily.
    Grade 2 or 3 RPED that does not improve to at least grade 1 within 3 weeks: Discontinue permanently.

    Left ventricular ejection fraction (LVEF) reduction
    Interruption of treatment should occur in patients with asymptomatic absolute decrease of greater than 10% in LVEF compared to baseline and the ejection fraction is below the institution's lower limit of normal (LLN).
    If LVEF recovers, treatment can be restarted but dose reduced by one dose level with careful monitoring should be performed.
    Grade 3 or 4 left ventricular dysfunction (LVD) or clinically significant reduction in LVEF which does not recover within 4 weeks: Permanently discontinue treatment.

    When used in combination both treatments should be modified simultaneously unless stated as an exception, see manufacturers information for further details.


    Children under 18 years
    Retinal blood vessel occlusion

    Precautions and Warnings

    Predisposition to gastrointestinal perforation
    Predisposition to retinal detachment
    Predisposition to retinal vein occlusion
    Intraocular hypertension
    Left ventricular dysfunction
    Moderate hepatic impairment
    New York Heart Association class II failure
    New York Heart Association class III failure
    New York Heart Association class IV failure
    Serious cardiac arrhythmias
    Severe renal impairment
    Uncontrolled diabetes mellitus
    Uncontrolled glaucoma
    Uncontrolled hypertension
    Within 6 months of an acute coronary syndrome episode

    Advise ability to drive/operate machinery may be affected by side effects
    Confirm BRAF V600 mutation status of tumour prior to treatment
    Treatment to be initiated and supervised by a specialist
    Consult local policy on the safe use of oral anti-cancer drugs
    Staff: Not to be handled by pregnant staff
    Assess LVEF before treatment, 1 month after starting, then every 3 months
    Monitor blood pressure pre-treatment and periodically thereafter
    Advise patient to stop and contact Dr if severe/persistent abdominal pain
    Consider myocarditis if new or worsening cardiac signs or symptoms occur
    If visual disturbances occur, perform ophthalmic evaluation
    Monitor closely for signs and sypmtoms of Stevens-Johnson syndrome
    Monitor for signs and symptoms of infection after treatment
    Monitor for signs and symptoms of pneumonitis
    Monitor hepatic function every 4 weeks for 6 months, or as indicated
    Advise patient of thromboembolic symptoms and to report them if they occur
    Advise patient to report any blurred vision or any other eye symptoms
    Discontinue or suspend treatment if grade 4 toxicities occur
    Discontinue treatment if interstitial lung disease develops
    Suspend treatment if DRESS is suspected
    Suspend treatment if pneumonitis is suspected
    Suspend treatment if Stevens-Johnson syndrome is suspected
    Consider discontinuation if symptoms of severe rhabdomyolysis occur
    Discontinue if pulmonary embolism occurs
    Discontinue if retinal vein occlusion occurs
    Discontinue if treatment related pneumonitis is diagnosed
    Discontinue treatment and/or reduce dose in grade 2 or greater RPED
    Interrupt treatment if patients temperature is 38 degrees C or more
    Suspend treatment if grade 3 or intolerable grade 2 toxicities
    Suspend treatment if interstitial lung disease is suspected
    Suspend treatment if LVEF decrease of 10% below baseline
    May cause impaired fertility
    Female: Barrier or non-hormonal contraception advised during treatment
    Female: Contraception required during and for 4 months after treatment
    Advise patient of risk of bleeding

    Haemorrhagic events have occurred in patients taking trametinib, if such events occur patients should be treated as clinically indicated. The potential for these events in patients with low platelets (less than 75,000) is not established.

    Concomitant use of antiplatelet and anticoagulant therapy may increase risk of haemorrhage.

    Signs and symptoms of rhabdomyolysis should warrant clinical evaluation and appropriate treatment.

    If patients present with new or progressive pulmonary symptoms including suspected interstitial lung disease (ILD) or pneumonitis, trametinib treatment should be withheld. Following diagnosis of ILD or pneumonitis, trametinib treatment should be discontinued.

    LVD due to myocarditis has been reported in patients taking trametinib and dabrafenib, which fully recovered once treatment stopped. Myocarditis should be considered following any new or worsening cardiac signs or symptoms.

    Sarcoidosis has been reported in patients treated with trametinib in combination with dabrafenib. In cases of a diagnosis with sarcoidosis, relevant treatment should be considered. It is important that sarcoidosis is not misinterpreted as disease progression.

    Pregnancy and Lactation


    Trametinib is contraindicated during pregnancy.

    The manufacturer recommends that trametinib should not be administered to pregnant women. At the time of writing there is limited published information regarding the use of trametinib during pregnancy in humans. Animal studies have shown reproductive toxicity including decreased foetal body weight, incomplete ossification and skeletal malformations.


    Trametinib is contraindicated during breastfeeding.

    The manufacturer recommends that trametinib should not be administered to breastfeeding mothers. At the time of writing there is limited published information regarding the use of trametinib during breastfeeding. It is not known whether trametinib is excreted into human breast milk, a risk to neonates cannot be excluded.


    Tablets to be taken whole and at similar times of the day. At least 1 hour before or 2 hours after a meal.

    Advise patients to seek urgent medical attention if they develop severe abdominal pain.

    Advise patient if a dose is missed to take as soon as remembered only if it is more than 12 hours until the next scheduled dose. Patients should not take extra tablets to make up for the missed dose.

    Males taking trametinib in combination with dabrafenib should be informed of potential risk of impaired irreversible spermatogenesis.

    Advise female patients to use highly effective barrier or non-hormonal contraception during treatment and for 4 months after.

    Advise patients ability to drive or operate machinery may be affected by side effects.

    Advise patient to report any muscle pain, tenderness or weakness.

    Advise patient to report any skin reactions, pain, erythema, pruritus.

    Advise patient to report any symptoms of pulmonary embolism / deep vein thrombosis.

    Advise patient to report any visual disturbances.

    Side Effects

    Abdominal pain
    Actinic keratosis
    Alanine aminotransferase increased
    Aspartate aminotransferase increased
    Blurred vision
    Cardiac failure
    Creatine phosphokinase increased
    Cutaneous lesions
    Decreased appetite
    Decreased ejection fraction
    Drug rash with eosinophilia and systemic symptoms (DRESS)
    Dry mouth
    Dry skin
    Exfoliative dermatitis
    Facial oedema
    Gamma glutamyl transferase (GGT) increased
    Gastro-intestinal perforation
    Hypersensitivity reactions
    Impaired vision
    Increase in alkaline phosphatase
    Influenza-like symptoms
    Interstitial lung disease
    Left ventricular failure
    Mucosal inflammation
    Muscle spasm
    Night sweats
    Painful extremities
    Palmar-Plantar Erythrodysaesthesia syndrome
    Periorbital oedema
    Peripheral oedema
    Primary melanoma
    Pustular rash
    Renal failure
    Retinal detachment
    Retinal vein occlusion
    Seborrhoeic keratosis
    Skin fissures
    Squamous cell carcinoma
    Stevens-Johnson syndrome
    Urinary tract infections
    Visual disturbances


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: March 2018

    Reference Sources

    Summary of Product Characteristics: Mekinist 0.5 mg film-coated tablets. Novartis Pharmaceutical UK Ltd. Revised July 2022.
    Summary of Product Characteristics: Mekinist 2 mg film-coated tablets. Novartis Pharmaceutical UK Ltd. Revised July 2022. Government departments. Medicines and Healthcare products Regulatory Agency. Drug Safety Updates. Trametinib (Mekinist): Risk of gastrointestinal perforation and colitis. Available at: Last accessed: 15 January 2018.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.